1 Year of Ocrevus Not Linked to Higher Risk of Brain Infection PML
One year of Ocrevus (ocrelizumab) treatment does not increase the risk for a rare brain infection ā called progressive multifocal leukoencephalopathy (PML) ā in people with multiple sclerosis (MS), a study suggests. The study, āRisk Assessment of Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis Patients during…